CardiaTec raises £1.4m to combat cardiovascular disease with AI

pharmafile | July 7, 2022 | News story | Business Services  

CardiaTec Biosciences has secured a £1.4 million pre-seed investment led by Laidlaw Scholars Ventures and APEX Ventures. The company is developing a target discovery platform leveraging AI to make sense of large-scale multiomic cardiovascular data.

CardiaTec is AI drug target discovery company, specialising in cardiovascular disease. Its proprietary platform unravels relationships that span across every level of biology, from gene variation, methylation, and expression, to their connection to proteomic and metabolomic functions, to best understand disease development.   

“Cardiovascular disease research has been subject to some very positive recent events,” said Raphael Peralta, CEO of CardiaTec. “We strongly believe, after several decades of stagnated investment and innovation, cardiovascular disease is re-emerging with newfound interest, driven by the application of AI in being able to drive new and meaningful insights to help meet patients’ needs.”

Peralta concluded: “CardiaTec finds itself incredibly well placed to help drive innovation forwards within this space, now supported by a great syndicate of investors.”

The investment round was led by Laidlaw Scholars Ventures (LSV) and APEX Ventures. The funding for CardiaTec marks the first investment from LSV, which is the recently formed investment arm of the Laidlaw Foundation.

The Cambridge company was co-founded by Raphael Peralta (CEO), Thelma Zablocki (COO) and Dr. Namshik Han (CTO). Other participants in the funding round included Crista Galli Ventures, o2h ventures and Cambridge Enterprise.

“We are delighted to support this exceptional team on their mission to improve patient outcomes by using AI for good,” said LSV chief investment officer, Niall Santamaria.

“Despite the prevalence of cardiovascular ailments, there has been significant under-investment, so we believe these funds will provide CardiaTec with the opportunity to unearth treatments that make a real difference to patients.”

Ana Ovey

Related Content

No items found

Latest content